To evaluate whether Endoscopic Ultrasound assessment of benign esophageal strictures before starting treatment can help in predicting prognosis and guide further therapy

Role of EUS in predicting prognosis and guiding therapy in benign esophageal strictures

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/026178

Enrollment

Registered

2020-06-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K222- Esophageal obstruction

Interventions

Intervention1: Endoscopic esophageal stricture dilatation with intralesional steroid injection: Endoscopic esophageal stricture dilatation with intralesional steroid injection after baseline Endoscopi

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with esophageal strictures post corrosive ingestion 2.Patients with peptic esophageal strictures 3.Patients with post-anastomotic esophageal strictures 4.Patients with strictures secondary to pill esophagitis

Exclusion criteria

Exclusion criteria: 1.Stricture length > 6cm 2.Malignant strictures 3.Patients with post-radiation strictures 4.Patients with strictures which are non- negotiable with miniprobe EUS 5.Patients who have not given consent 6.Patients who had undergone dilatation or intralesional steroid injection previously

Design outcomes

Primary

Measure	Time frame
1.Evaluate the role of miniprobe EUS in predicting the response to endoscopic dilatation in benign esophageal stricture. 2.Evaluate the role of intralesional steroid injections from the start of dilatation program in guiding management of refractory benign esophageal stricture (RBES). Timepoint: After baseline Endoscopic Ultrasound assessment patients will be started on dilatation therapy with or without intralesional steroids depending on the study arm. Dilatation will be done every two weekly till target dilatation of 15 mm is achieved. 5 sessions of dilatation will be given after which (after 10 weeks) patients will be assessed for response to therapy. Inability to dilate to 15 mm is treatment failure- refractory stricture.	—

Measure

Time frame

1.Evaluate the role of miniprobe EUS in predicting the response to endoscopic dilatation in benign esophageal stricture. 2.Evaluate the role of intralesional steroid injections from the start of dilatation program in guiding management of refractory benign esophageal stricture (RBES). Timepoint: After baseline Endoscopic Ultrasound assessment patients will be started on dilatation therapy with or without intralesional steroids depending on the study arm. Dilatation will be done every two weekly till target dilatation of 15 mm is achieved. 5 sessions of dilatation will be given after which (after 10 weeks) patients will be assessed for response to therapy. Inability to dilate to 15 mm is treatment failure- refractory stricture.

—

Secondary

Measure	Time frame
Recurrence of esophageal strictures and need for endoscopic therapy during trial period.Timepoint: Recurrence of a stricture is when patient re-develops symptoms of dysphagia after successful treatment. Patients will be followed till end of study period- 5 months for stricture recurrence.	—

Countries

India

Contacts

Public ContactProf Dr Rakesh Kochhar

Post Graduate Institute of Medical Education and Research

dr_kochhar@hotmail.com9815699565

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026